share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  2024/08/14 04:18

Moomoo AI 已提取核心信息

Adial Pharmaceuticals reported Q2 2024 financial results with R&D expenses increasing 136% to $1.0 million and G&A expenses rising 22% to $1.3 million compared to Q2 2023. The company ended the quarter with $3.3 million in cash and cash equivalents, bolstered by approximately $3.8 million from warrant exercises and $411,000 from ATM equity sales during the period.The company has initiated a Phase 1 pharmacokinetic study of AD04 with an estimated cost of $1.4 million and plans to begin a Phase III study in the first half of 2025. Management expects to use $10-15 million in cash during the next twelve months for AD04 development and corporate expenses, with $5-10 million contingent on implementing accelerated development plans.Looking ahead, Adial will require additional financing to execute its overall business strategy, including two additional Phase 3 trials for AD04 estimated at $8-12 million each. The company raised an additional $3.7 million in July 2024 through ATM equity sales, though management notes current cash is not sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
Adial Pharmaceuticals reported Q2 2024 financial results with R&D expenses increasing 136% to $1.0 million and G&A expenses rising 22% to $1.3 million compared to Q2 2023. The company ended the quarter with $3.3 million in cash and cash equivalents, bolstered by approximately $3.8 million from warrant exercises and $411,000 from ATM equity sales during the period.The company has initiated a Phase 1 pharmacokinetic study of AD04 with an estimated cost of $1.4 million and plans to begin a Phase III study in the first half of 2025. Management expects to use $10-15 million in cash during the next twelve months for AD04 development and corporate expenses, with $5-10 million contingent on implementing accelerated development plans.Looking ahead, Adial will require additional financing to execute its overall business strategy, including two additional Phase 3 trials for AD04 estimated at $8-12 million each. The company raised an additional $3.7 million in July 2024 through ATM equity sales, though management notes current cash is not sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
Adial Pharmaceuticals报告2024年第二季度财务结果，研发费用比2023年第二季度增加了136%，达到100万美元，管理费用则上升22%，达到130万美元。公司在本季度末拥有330万美元的现金及现金等价物，资金得益于大约380万美元的认股权证行使和41.1万美元的ATM股票销售。公司已启动AD04的第一阶段药代动力学研究，预计成本为140万美元，并计划于2025年上半年启动第三阶段研究。管理层预计在未来十二个月内将使用1000万至1500万美元的现金用于AD04开发和公司费用，其中500万至1000万美元将取决于加速开发计划的实施。展望未来，Adial将需要额外融资以执行其整体业务策略，包括预计需要800万至1200万美元的两个额外的AD04第三阶段试验。公司在2024年7月通过ATM股票销售再融资370万美元，尽管管理层指出当前现金不足以支持公司在未来十二个月的运营，这对其作为持续经营的能力产生了重大怀疑。
Adial Pharmaceuticals报告2024年第二季度财务结果，研发费用比2023年第二季度增加了136%，达到100万美元，管理费用则上升22%，达到130万美元。公司在本季度末拥有330万美元的现金及现金等价物，资金得益于大约380万美元的认股权证行使和41.1万美元的ATM股票销售。公司已启动AD04的第一阶段药代动力学研究，预计成本为140万美元，并计划于2025年上半年启动第三阶段研究。管理层预计在未来十二个月内将使用1000万至1500万美元的现金用于AD04开发和公司费用，其中500万至1000万美元将取决于加速开发计划的实施。展望未来，Adial将需要额外融资以执行其整体业务策略，包括预计需要800万至1200万美元的两个额外的AD04第三阶段试验。公司在2024年7月通过ATM股票销售再融资370万美元，尽管管理层指出当前现金不足以支持公司在未来十二个月的运营，这对其作为持续经营的能力产生了重大怀疑。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。